5-Amino-tetrazole derivatives, processes for their preparation and pharmaceutical compositions containing them
申请人:GLAXO GROUP LIMITED
公开号:EP0049049A1
公开(公告)日:1982-04-07
The invention relates to compounds of the general formula (I)
and physiologically acceptable salts, hydrates and bioprecursors thereof in which
R, represents C1-14 alkyl, cycloalkyl, aralkyl, trifluoroalkyl, heteroaralkyl, alkenyl, alkynyl, or alkyl substituted by hydroxy, alkoxy, amino, alkylamino, dialkylamino or cycloalkyl; and R2 represents hydrogen or a C1-4 alkyl group; or
R1 and R2 together with the nitrogen atom to which they are attached form a 5-10 membered ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom selected from oxygen and sulphur;
Alk represents a straight or branched C1-6 alkylene chain.
Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions the furan or thiophen ring optionally bearing a further substituent R4 adjacent to the group R1R2N-Alkyl-; or 0 represents a thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 4-positions, the thiophen ring optionally bearing a further substituent R4 adjacent to the group R1R2NAlk with the proviso that when the group R1R2NAIlk is in the 4-position then the group R4 is in the 5-position; or Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions;
R4 represents halogen or C,., alkyl which may be substituted by hydroxy or C1-4 alkoxy;
R3 represents hydrogen, alkyl, alkenyl, aralkyl, C2-6 alkyl substituted by hydroxy, alkoxy or C,., alkanoyloxy;
X and Y, which may be the same or different, each represent oxygen, sulphur, methylene or a bond;
n represents zero, 1, 2 or 3 and m represents an interger from 2 to 5 with the provisos that (a) the total number of atoms in the chain X(CH2)nY(CH2)m is an integer from 3 to 8 and (b) when X and Y represent oxygen or sulphur then n is 2 or 3.
The compounds show pharmacological activity as selective histamine H2-antagonists.
本发明涉及通式 (I) 的化合物
及其生理上可接受的盐、水合物和生物前体,其中
R,代表 C1-14 烷基、环烷基、芳基、三氟烷基、杂烷基、烯基、炔基或被羟基、烷氧基、氨基、烷基氨基、二烷基氨基或环烷基取代的烷基;R2 代表氢或 C1-4 烷基;或
R1 和 R2 与它们所连接的氮原子一起形成一个 5-10 个成员的环,该环可以是饱和的,也可以含有至少一个双键,可以是未取代的,也可以被一个或多个 C1-3 烷基或羟基取代,和/或可以含有另一个选自氧和硫的杂原子;
烷基代表直链或支链 C1-6 亚烷基链。
Q 代表呋喃环或噻吩环,通过 2-位和 5-位的键与分子的其余部分结合,呋喃环或噻吩环可选择带有与基团 R1R2N-Alkyl- 相邻的另一个取代基 R4;或 0 代表噻吩环,通过 2 位和 4 位的键与分子的其余部分结合,该噻吩环可选择带有与基团 R1R2NAlk 相邻的另一个取代基 R4,但当基团 R1R2NAIlk 位于 4 位时,基团 R4 位于 5 位;或 Q 代表苯环,通过 1 位和 3 位或 1 位和 4 位的键与分子的其余部分结合;
R4 代表卤素或可被羟基或 C1-4 烷氧基取代的 C,...烷基;
R3 代表氢、烷基、烯基、芳烷基、被羟基、烷氧基或 C...烷酰氧基取代的 C2-6 烷基;
X 和 Y 可以相同或不同,各自代表氧、硫、亚甲基或键;
n 代表零、1、2 或 3,m 代表 2 至 5 之间的整数,但前提是:(a) 链中 X(CH2)nY(CH2)m 的原子总数为 3 至 8 之间的整数;(b) 当 X 和 Y 代表氧或硫时,n 为 2 或 3。
这些化合物具有选择性组胺 H2-拮抗剂的药理活性。